Syndax Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of June 2026: 30.04%

Syndax Pharmaceuticals Inc (SNDX) has an Asset Resilience Ratio of 30.04% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SNDX net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$211.38 Million
Cash + Short-term Investments

Total Assets

$703.65 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how Syndax Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Syndax Pharmaceuticals Inc total assets.

Liquid Assets Composition Over Time

This chart breaks down Syndax Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Syndax Pharmaceuticals Inc (SNDX) investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $211.38 Million 30.04%
Total Liquid Assets $211.38 Million 30.04%

Asset Resilience Insights

  • Very High Liquidity: Syndax Pharmaceuticals Inc maintains exceptional liquid asset reserves at 30.04% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Syndax Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Syndax Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
ALK-Abelló A/S
CO:ALK-B
Biotechnology 0.98%
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Biotechnology 6.89%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
BB Biotech AG
SW:BION
Biotechnology 92.97%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Nanobiotix
NASDAQ:NBTX
Biotechnology 4.71%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590
Biotechnology 10.55%

Annual Asset Resilience Ratio for Syndax Pharmaceuticals Inc (2011–2025)

The table below shows the annual Asset Resilience Ratio data for Syndax Pharmaceuticals Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 52.62% $278.76 Million $529.71 Million -6.54pp
2024-12-31 59.16% $428.83 Million $724.82 Million +13.12pp
2023-12-31 46.04% $282.19 Million $612.88 Million -36.42pp
2022-12-31 82.46% $410.04 Million $497.24 Million +32.46pp
2021-12-31 50.01% $224.87 Million $449.66 Million -9.15pp
2020-12-31 59.15% $177.82 Million $300.61 Million +3.80pp
2019-12-31 55.36% $35.17 Million $63.52 Million -0.81pp
2018-12-31 56.16% $47.14 Million $83.94 Million -12.94pp
2017-12-31 69.11% $94.81 Million $137.19 Million -5.64pp
2016-12-31 74.75% $81.49 Million $109.01 Million +3.43pp
2015-12-31 71.32% $64.11 Million $89.90 Million +54.16pp
2014-12-31 17.16% $2.20 Million $12.82 Million -7.22pp
2013-12-31 24.38% $4.16 Million $17.06 Million +18.36pp
2012-12-31 6.03% $91.00K $1.51 Million -6.78pp
2011-12-31 12.81% $613.00K $4.79 Million --
pp = percentage points

About Syndax Pharmaceuticals Inc

NASDAQ:SNDX USA Biotechnology
Market Cap
$1.58 Billion
Market Cap Rank
#7053 Global
#2184 in USA
Share Price
$17.68
Change (1 day)
+2.31%
52-Week Range
$13.11 - $25.15
All Time High
$28.98
About

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. Th… Read more